Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
ALK inhibitors cover anaplastic lymphoma kinase and activin receptor-like kinases, two unrelated groups named ALK. Anaplastic lymphoma kinase was identified in 1994 as a tyrosine kinase fused to nucleophosmin (NPM) in a non-Hodgkin lymphoma. In 2007 a fusion with echinoderm microtubule-associated protein-like 4 (EML4) was found in non-small-cell lung cancer. Crizotinib, TAE684, brigatinib and entrectinib inhibit anaplastic lymphoma kinase, and entrectinib also blocks tropomyosin receptor kinases (Trk). Activin receptor-like kinases (ALKs) are type I receptors for transforming growth factor beta (TGF-β) family ligands. A 83-01 inhibits ALK4, ALK5 and ALK7 and blocks Smad signaling by TGF-β. Vactosertib also targets ALK4 and ALK5, while LDN193189 and DMH-1 inhibit the bone morphogenetic protein receptor ALK2.
ALK ligand-1 is a specific ligand for Anaplastic Lymphoma Kinase (ALK). It serves as a critical component in the synthesis of PROTAC ALK degrader-4, facilitating targeted protein degradation. This compound is valuable for research applications aimed at studying ALK-mediated pathways and developing novel therapeutic strategies in oncology.
Out of stock
All 3 sizes